The study protocol was registered in the International Prospective Register of systematic reviews PROSPERO (CRD420251002447)
The drug was retatrutide, an investigational and highly potent weight-loss drug (allegedly more powerful than Ozempic, Wegovy, and the like)
Injectable supplementation offers higher bioavailability than oral forms
The study population consisted of hospitalized adults diagnosed with AH, identified using International Classification of Diseases, 10th revision, and Clinical Modification codes
Dos and Donts for Optimal Results Maximizing the benefits of Lemon Bottle fat dissolving treatments goes beyond the injection room
Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited